Navigation Links
Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine,in Glioma Presented at American Association of Neurological,Surgeons Annual Meeting

WASHINGTON--(BUSINESS WIRE)--Apr 16, 2007 - Antigenics Inc. (NASDAQ: AGEN) today announced an oral presentation of updated data from a Phase 1/2 investigator-sponsored trial of the company's investigational cancer vaccine Oncophage(R) (vitespen) in recurrent, high-grade glioma at the 75th annual meeting of the American Association of Neurological Surgeons (AANS; abstract #606). Preliminary results from the study, being conducted at the Brain Tumor Research Center at the University of California, San Francisco, showed that Oncophage vaccination was associated with significant tumor-specific immune response in all 12 treated patients from baseline (P less than .001), as determined using three separate immune response assessments. Of the 12 patients treated, four continue to receive Oncophage and eight have completed treatment and are evaluable for overall survival. Seven of these eight evaluable patients have exceeded the historical median benchmark of 6.5 months survival from time of recurrence.

"In this trial we have observed a correlation between immune response as a result of Oncophage vaccination and potential clinical benefit," said Andrew T. Parsa, MD, PhD, assistant professor in the department of neurological surgery at the University of California, San Francisco, and recipient of the 2007 Young Investigator Award at AANS. "Understanding that the patients in this trial represent the most challenging patient population to treat, we are highly encouraged by the prolonged improvement in overall survival compared with historical controls."

Commenting on the paper presented at AANS, Henry Brem, MD, director of neurosurgery at Johns Hopkins, noted, "This is an encouraging study of a therapeutic cancer vaccine that targets multiple tumor antigens, supported by rigorous immunomonitoring. A larger Phase 2 trial is certainly warranted to evaluate efficacy." Dr. Brem is a developer of Gliadel(R) Wafer (polife
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
7. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
Post Your Comments:
(Date:12/24/2014)... Tianyin Pharmaceutical Co., Inc. (NYSE MKT: ... biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... the Company achieved the Public Notice (Gong Shi) ... of TPI,s Qionglai Facility (QLF) from the China ... period is a significant procedure of GMP certification ...
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
(Date:12/22/2014)... a privately-held medical products and technologies company, today announced ... Officer of the company, effective December 22, 2014. ... Board of Directors of ConvaTec thanks Mr. Berger for ... years," said Magnus Lundberg , the Chairman of ... company is well positioned for the future."  The company ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
(Date:12/25/2014)... Among early stage breast cancer patients who undergo chemotherapy ... will eventually develop leukemia as a result of their ... from a review of more than 20,000 breast cancer ... that the risk for developing treatment-related leukemia, though low, ... "The frequency of bone marrow cancers such as leukemia ...
(Date:12/25/2014)... SmileStix ” was featured on NewsWatch as part of its ... on the iOS, Android, and Windows markets. Andrew Tropeano, a ... review and shared with viewers how this is an application ... goes, “A picture says a thousand words.” It’s true. There ... image, because each picture holds a unique and special meaning. ...
(Date:12/25/2014)... Parker & Sons, Inc. an industry leader ... quality regarding heating, cooling and plumbing services in the ... the “Queen of Clean” for impressive contractor services in ... over the years for providing outstanding quality customer service ... services for both homeowners and businesses. Linda Cobb, known ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Connie Casad, ... and functional medicine advocate with 30 years of practice ... to evaluate the health benefits of dietary detoxification. The ... new participants following excellent results from test patients who ... asked to explain her interest in conducting the study, ...
(Date:12/24/2014)... 2014 Dr. Vu Ho, a Dallas ... his practice and med-spa with the addition of new ... of cosmetic treatments and services. , “Silk Peel is ... says Dr. Ho. “As a result it can address ... sun spots, discolorations or blemishes.” , Similar to microdermabrasion, ...
Breaking Medicine News(10 mins):Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2
... that the strongest risk factors for atrial fibrillation in both ... While hypertension is a well known risk factor for AF, ... later occurrence of AF has not been documented earlier". ... and is a major risk factor for heart failure (risk ...
... administering a common chemotherapy drug before bone tumors took ... once introduced, to seed and grow more easily. ... some cancers metastasize to bone, and could eventually result ... the Department of Periodontics and Oral Medicine at the ...
... (HealthDay News) -- People with HIV/AIDS are four times more ... the general population, a new study finds. The findings ... researchers from the University of California, San Francisco (UCSF). In ... the heart suddenly and unexpectedly stops beating. The researchers ...
... that looked at the hunger trends over a 10-year period ... more than one in seven, face the threat of hunger. ... reported that one in nine seniors faced the threat of ... agricultural and consumer economics and executive director of the National ...
... team of international scientists has made a significant breakthrough in ... of liver cancer. By identifying several new genes frequently mutated ... better understanding of how bile duct cancers develop. Their discovery ... Duct Cancer, or Cholangiocarcinoma, is a fatal cancer with a ...
... University researcher Julia Frugoli has received $132,769 as the ... the National Science Foundation to continue her study of ... to control their growth and development. The work ... of Agriculture, Forestry & Life Sciences, genetics and biochemistry ...
Cached Medicine News:Health News:Palpitations are predictive of future atrial fibrillation 2Health News:Palpitations are predictive of future atrial fibrillation 3Health News:'Fertilizing' bone marrow helps answer why some cancers spread to bones 2Health News:People With HIV at Higher Odds of Sudden Cardiac Death 2Health News:Great recession reflux amounts to more hunger among seniors 2Health News:Scientists make breakthrough in bile duct cancer with discovery of new gene mutations 2Health News:Scientists make breakthrough in bile duct cancer with discovery of new gene mutations 3Health News:Clemson professor awarded nearly $600,000 4-year grant to study language of plants 2
... & Nephew offers a wide variety of ... available in both partially threaded and fully ... are the 5.5 and 7.0 mm products. ... the surgeon's job a little easier. Ratchet ...
... Nailing System is one of the first ... for either an antegrade or a retrograde ... , ,Stryker Orthopaedics Trauma has now created ... together all the capabilities and benefits of ...
... Humeral Nail System has been designed to ... noninvasive treatments have historically failed to give ... blend of strength and flexibility. Ideally suited ... titanium alloy is twice that of stainless ...
... nailing techniques have largely replaced the use of plates ... The use of rods or pins in the forearm ... has been no way to lock the pins or ... a non-locked nail is back out of the implant. ...
Medicine Products: